



## **Network Oncology, Inc. Appoints Manfred G. von Nostitz as CEO, President, and Director**

**Vancouver, B.C., April 14, 2015** – Network Oncology Inc. (“Network Oncology”, “the Company”) announces the appointment of Manfred G. von Nostitz as CEO, President, and Director of Network Oncology. Mr. von Nostitz is a veteran foreign business consultant specializing in the Asia Pacific region. With over three decades in the Canadian Foreign service he held the posts of Director General for South and Southeast Asia, the U.N. and Security & Intelligence, and went on to serve as High Commissioner to Malaysia and Brunei and as Canadian Ambassador to Pakistan/Afghanistan, Thailand, Laos and Myanmar. Fluent in multiple languages, he holds a B.A. (Hon.) degree Arts & Science and an M.A. in Political Science from the University of Toronto.

Since 2005 Mr. von Nostitz has served as President, Asia Pacific, of the Corporate Council Consultancy S.A., based in Kuala Lumpur. In this role, he regularly advises Western companies on business opportunities in the Asia Pacific region. He brings a broad career spectrum of business and government relations experience derived from over 30 years of work as an advisor, diplomat and corporate director in the region. Formerly the VP of Shanghai based Profound Automotive in Southeast Asia and Principal Advisor to the Malaysian Southern Bank Group, he enjoys extensive experience with corporate acquisitions, technology transfers, investor relations and merger implementation.

Network Oncology currently possesses a well-diversified portfolio of oncological drug assets and plans to use its technical and commercial expertise to develop, launch, market and sell their portfolio of value-added products and services throughout Europe while offering significant cost savings to patients and payers. The appointment of Manfred von Nostitz, heralds an era of huge opportunities for the Company's oncological products on the Pacific Asia region.

Bill Thomas, CFO and Director commented, "The high value - lower cost product value construct at the base of our oncological pharmaceutical products forms a perfect fit for the expanse of markets now available to the Company through the networks and decades of experience represented by Mr. von Nostitz. The potential of this Company has expanded to a worldwide focus from our base of operations in Germany and Europe.

The Company also announces it has accepted the resignations of Sean Maenpaa and Shane Ring as officers and or directors to Network Oncology Inc.

### **About Network Oncology Inc.**

Network has acquired and is currently selling a core portfolio of oncology generic products for the European markets with possible expansion to other territories. The Company is commercially focused and is dedicated to serving the oncology marketplace by understanding local market dynamics and its customers unmet needs. In addition, the Company has the ability to identify and pursue profitable segments of the oncology market in conjunction with providing value-added products and support services for its portfolio. Network also possesses the knowledge and capability to develop and commercialize differentiated versions of existing cancer products where an unmet need currently exists.

### **Further Information**

Further details are available under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com), and the Company's profile on the CSE's website at [www.cnsx.ca](http://www.cnsx.ca).

For further information please contact:

Bill Thomas, CFO, and Director

Telephone: +353(0)874601340

E-mail: [info@networkoncology.com](mailto:info@networkoncology.com)

Website: [www.networkoncology.com](http://www.networkoncology.com)

Canadian Securities Exchange (CSE): Symbol **NOI**

Deutsche Boerse Xetra - Frankfurt Stock Exchange: Symbol **2NY**; WKN#: A11827

**Forward-Looking Information:** This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company including future plans for the development and sale of oncological pharmaceutical products. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to

be correct. Forward-looking statements contained in this press release are made as of the date of this press release. the Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.